Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes
Journal of Diabetes Science and Technology · 2024
DOI: 10.1177/19322968231159657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Science and Technology, 2024. Verfasst von Julia Kölle und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Blood Glucose Self-Monitoring, Blood Glucose. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FIND.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
FIND, the global alliance for diagnostics, identified the nonmarket-approved continuous glucose monitoring (CGM) system, FiberSense system (FBS), as a potential device for use in low- and middle-income countries. Together with two market-approved, factory-calibrated CGM systems, namely, the FreeStyle Libre 2 (FL2) and the GlucoRx AiDEX (ADX), the FBS was subjected to a clinical performance evaluation.
Methods
Thirty adult participants with type 1 diabetes were enrolled. The study was mainly conducted at home, with three in-clinic sessions conducted over the study period of 28 days. Comparator measurements were collected from capillary samples, using a high-quality blood glucose monitoring system.
Results
Data from 31, 70, and 78 sensors of FBS, FL2, and ADX, respectively, were included in the performance analysis. The mean absolute relative differences between CGM and comparator data for FBS, FL2, and ADX were 14.7%, 9.2%, and 21.9%, and relative biases were −2.1%, −2.5%, and −18.5%, respectively. Analysis of individual sensor accuracy revealed low, moderate, and high sensor-to-sensor variability for FBS, FL2, and ADX, respectively. Sensor survival probabilities until the end of sensor life were 47.2% for FBS (28 days), 71.3% for FL2 (14 days), and 48.4% for ADX (14 days).
Conclusions
The results of FBS were encouraging enough to conduct further performance and usability evaluations in a low- and middle-income country. The results of FL2 mainly agreed with existing studies, whereas ADX showed substantial deviations from previously reported results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
- FIND, Geneva, Switzerland.
ORCID-Profile: Manuel Eichenlaub, Jochen Mende, Beatrice Vetter, Stefan Pleus, Guido Freckmann
Förderung
- FIND
Zitieren
APA
Kölle, J., Eichenlaub, M., Mende, J., Link, M., Vetter, B., Safary, E., Pleus, S., Haug, C., & Freckmann, G. (2024). Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968231159657
Vancouver
Kölle J, Eichenlaub M, Mende J, Link M, Vetter B, Safary E, et al. Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology. 2024. doi:10.1177/19322968231159657
BibTeX
@article{Klle2024,
author = {Kölle, Julia and Eichenlaub, Manuel and Mende, Jochen and Link, Manuela and Vetter, Beatrice and Safary, Elvis and Pleus, Stefan and Haug, Cornelia and Freckmann, Guido},
title = {Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes},
journal = {Journal of Diabetes Science and Technology},
year = {2024},
doi = {10.1177/19322968231159657}
}
EUVIMED